FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100045991> ?p ?o ?g. }

• W2100045991 endingPage "286" @default.
• W2100045991 startingPage "278" @default.
• W2100045991 abstract "H 1 ‐receptor antagonists are considered central to the treatment of atopic dermatitis (AD)‐associated pruritus and are widely used in the treatment of AD despite a lack of double‐blind, randomized clinical trials. In this study we analyzed the effects of the long‐term use of cetirizine on the severity, natural history, and treatment of AD. In the prospective, multi‐country, double‐blind, randomized, placebo‐controlled Early Treatment of the Atopic Child (ETAC ™ ) study, 817 infants (12–24 months of age) who suffered from AD at study entry and with a history of atopic disease in a parent or sibling were treated for 18 months with either cetirizine (0.25 mg/kg) or placebo twice daily. All concomitant medications for the treatment of AD were allowed but had to be recorded by the investigator in the case report form; the concomitant use of H 1 ‐antihistamines was discouraged. The primary end‐point for efficacy was the onset of asthma. Secondary parameters of efficacy, however, were the consumption of concomitant medications for AD (topical and systemic treatment) and the severity of symptoms related to AD, which was rated with the AD scale, SCORAD. The severity of AD, as measured by SCORAD, decreased significantly (p < 0.001) over the study period (18 months) in both groups. Other oral H 1 ‐antihistamines were significantly more often used in the placebo group than in the cetirizine group (24.9% vs. 18.6%, p = 0.03). The number of infants who developed urticaria during the study period was significantly lower with cetirizine treatment (placebo group: 16.2%; cetirizine group: 5.8%; p < 0.001). For the treatment of AD, mild topical corticosteroids (class I, e.g. hydrocortisone) were used in 41.6% of the patients (placebo group 41.6%, cetirizine group 41.7%) and moderate‐to‐potent topical corticosteroids (class II, III, IV) in 55.0% (respectively 56.4% and 53.5%). The duration of the use of topical moderate‐to‐potent corticosteroids differed between the cetirizine group and the placebo group (mean percentage of days: placebo 25.2, median 2.4; cetirizine mean 18.8, median 0.95 p = 0.067, Mann–Whitney test, not statistically significant). In sub‐groups of infants with a SCORAD of ≥ 25, this cortico‐sparing effect was statistically significant (placebo 35.1 vs. 25.8 in the cetirizine group; p = 0.014, Mann–Whitney test). In conclusion, in view of the proven safety of cetirizine, the use of this drug might help to reduce the duration and the amount of moderate‐to‐strong topical corticosteroids used in the treatment of infants and children with AD. However, further studies designed with the primary end‐point of AD are clearly indicated to confirm the benefits of the use of H 1 ‐antihistamines in the management of AD." @default.
• W2100045991 created "2016-06-24" @default.
• W2100045991 creator A5013013699 @default.
• W2100045991 date "2002-08-01" @default.
• W2100045991 modified "2023-10-18" @default.
• W2100045991 title "Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized, placebo-controlled trial (the ETAC^™ trial) over 18 months" @default.
• W2100045991 cites W1492883184 @default.
• W2100045991 cites W1599400847 @default.
• W2100045991 cites W1990010334 @default.
• W2100045991 cites W1991057344 @default.
• W2100045991 cites W1993135987 @default.
• W2100045991 cites W1994208124 @default.
• W2100045991 cites W1995665983 @default.
• W2100045991 cites W1996369191 @default.
• W2100045991 cites W1996903618 @default.
• W2100045991 cites W2062612302 @default.
• W2100045991 cites W2064873092 @default.
• W2100045991 cites W2065595327 @default.
• W2100045991 cites W2075706994 @default.
• W2100045991 cites W2076722766 @default.
• W2100045991 cites W2080398170 @default.
• W2100045991 cites W2096991001 @default.
• W2100045991 cites W2097877025 @default.
• W2100045991 cites W2109530751 @default.
• W2100045991 cites W2143138262 @default.
• W2100045991 cites W2158354903 @default.
• W2100045991 cites W2181619615 @default.
• W2100045991 cites W2593244680 @default.
• W2100045991 doi "https://doi.org/10.1034/j.1399-3038.2002.01047.x" @default.
• W2100045991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12390444" @default.
• W2100045991 hasPublicationYear "2002" @default.
• W2100045991 type Work @default.
• W2100045991 sameAs 2100045991 @default.
• W2100045991 citedByCount "178" @default.
• W2100045991 countsByYear W21000459912012 @default.
• W2100045991 countsByYear W21000459912013 @default.
• W2100045991 countsByYear W21000459912014 @default.
• W2100045991 countsByYear W21000459912015 @default.
• W2100045991 countsByYear W21000459912016 @default.
• W2100045991 countsByYear W21000459912017 @default.
• W2100045991 countsByYear W21000459912018 @default.
• W2100045991 countsByYear W21000459912019 @default.
• W2100045991 countsByYear W21000459912020 @default.
• W2100045991 countsByYear W21000459912021 @default.
• W2100045991 countsByYear W21000459912022 @default.
• W2100045991 countsByYear W21000459912023 @default.
• W2100045991 crossrefType "journal-article" @default.
• W2100045991 hasAuthorship W2100045991A5013013699 @default.
• W2100045991 hasConcept C126322002 @default.
• W2100045991 hasConcept C142724271 @default.
• W2100045991 hasConcept C16005928 @default.
• W2100045991 hasConcept C168563851 @default.
• W2100045991 hasConcept C187212893 @default.
• W2100045991 hasConcept C202061045 @default.
• W2100045991 hasConcept C204243189 @default.
• W2100045991 hasConcept C204787440 @default.
• W2100045991 hasConcept C27081682 @default.
• W2100045991 hasConcept C2776173921 @default.
• W2100045991 hasConcept C2778329239 @default.
• W2100045991 hasConcept C2779134260 @default.
• W2100045991 hasConcept C2779384505 @default.
• W2100045991 hasConcept C2779463773 @default.
• W2100045991 hasConcept C2780501606 @default.
• W2100045991 hasConcept C2991744798 @default.
• W2100045991 hasConcept C42219234 @default.
• W2100045991 hasConcept C71924100 @default.
• W2100045991 hasConceptScore W2100045991C126322002 @default.
• W2100045991 hasConceptScore W2100045991C142724271 @default.
• W2100045991 hasConceptScore W2100045991C16005928 @default.
• W2100045991 hasConceptScore W2100045991C168563851 @default.
• W2100045991 hasConceptScore W2100045991C187212893 @default.
• W2100045991 hasConceptScore W2100045991C202061045 @default.
• W2100045991 hasConceptScore W2100045991C204243189 @default.
• W2100045991 hasConceptScore W2100045991C204787440 @default.
• W2100045991 hasConceptScore W2100045991C27081682 @default.
• W2100045991 hasConceptScore W2100045991C2776173921 @default.
• W2100045991 hasConceptScore W2100045991C2778329239 @default.
• W2100045991 hasConceptScore W2100045991C2779134260 @default.
• W2100045991 hasConceptScore W2100045991C2779384505 @default.
• W2100045991 hasConceptScore W2100045991C2779463773 @default.
• W2100045991 hasConceptScore W2100045991C2780501606 @default.
• W2100045991 hasConceptScore W2100045991C2991744798 @default.
• W2100045991 hasConceptScore W2100045991C42219234 @default.
• W2100045991 hasConceptScore W2100045991C71924100 @default.
• W2100045991 hasIssue "4" @default.
• W2100045991 hasLocation W21000459911 @default.
• W2100045991 hasLocation W21000459912 @default.
• W2100045991 hasOpenAccess W2100045991 @default.
• W2100045991 hasPrimaryLocation W21000459911 @default.
• W2100045991 hasRelatedWork W1522130347 @default.
• W2100045991 hasRelatedWork W1941136997 @default.
• W2100045991 hasRelatedWork W2000814248 @default.
• W2100045991 hasRelatedWork W2003620798 @default.
• W2100045991 hasRelatedWork W2008791288 @default.
• W2100045991 hasRelatedWork W2100045991 @default.
• W2100045991 hasRelatedWork W2125555654 @default.
• W2100045991 hasRelatedWork W278642116 @default.
• W2100045991 hasRelatedWork W3035837530 @default.

• next